Santhera Pharmaceuticals intends to file for a conditional marketing authorization with the European Medicines Agency (EMA) for idebenone — to be marketed as Puldysa — as a treatment for respiratory dysfunction in Duchenne muscular dystrophy (DMD). As it continues to gather data on the therapy, the company…
News
Cure SMA and Parent Project Muscular Dystrophy (PPMD) have formed a strategic partnership with Prometheus Research to improve data collection and analysis for patients with spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). Both U.S. nonprofit groups have developed notable patient registry initiatives in the past decade. The…
Young boys with Duchenne muscular dystrophy (DMD) have a higher rate of bone fractures than healthy children, a retrospective study shows. The fractures are more frequent in lower limbs and decrease the patients’ ability to walk, leading to wheelchair dependence. The study, “Fractures and bone health monitoring in boys…
Restoring a functional dystrophin gene using the genome editing tool CRISPR-Cas9 corrected a common mutation behind Duchenne muscular dystrophy (DMD), exon 44 deletion, in mice and human cells, a study shows. The same…
New Enhanced Microdystrophin Versions May Help Restore Muscle Function in DMD, Mouse Study Suggests
Engineered small versions of dystrophin protein, known as microdystrophins, have shown the ability to enhance muscle strength and function in preclinical models of Duchenne muscular dystrophy (DMD). Researchers from the University of Washington have now developed enhanced versions of these microdystrophins that can overcome some of the…
Building on their international trade association’s relationship with the Muscular Dystrophy Association (MDA), two Virginia firefighters will set out on a 130-mile hike this month to raise awareness of the partnership, and to promote newborn screening for neuromuscular conditions. The firefighters — medic Joe Jarman and lieutenant Travis…
Vamorolone, an experimental treatment for Duchenne muscular dystrophy (DMD), combines the benefits of two existing therapies — prednisone and eplerenone — on heart and muscle health, but with less detrimental side effects, a study in animal models of the disease reports. The study, “Vamorolone targets dual nuclear receptors to treat…
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bath dissertation, she analyzed Brexit’s long-term impact…
With each new advance in medicine comes ethical dilemmas, from fertility treatments and newborn screening, to vaccinations, gene therapies and euthanasia. But rare diseases and the expensive therapies needed to treat them — particularly in an age of scarce economic resources — almost always entail “tragic choices,” warned Avraham Steinberg,…
To raise awareness and money to back efforts that help those living with muscular dystrophy (MD), the Muscular Dystrophy Association (MDA) has launched its venerable #MDAShamrocks campaign. More than 20,000 businesses throughout the nation are expected to participate in this, the 37th annual St. Patrick’s Day-themed program to…
Recent Posts
- I won’t apologize for having 3 children with Duchenne MD
- FDA clears trial testing Mesoblast cell therapy in kids with DMD
- Seeing ‘Les Misérables’ reminds me of the arc of my own life with DMD
- ‘Be Their Muscle’ MDA campaign marks 10 years of workouts, fundraising
- How to combat social isolation while growing older with muscular dystrophy